Serum Orexin-A Levels in Childhood Generalized Epilepsy Syndromes

Objectives: To evaluate the role of orexin-A in childhood generalized epilepsy by determining serum orexin-A levels in children with generalized epilepsy syndromes.Methods: This cross-sectional, case-control study included 21 children diagnosed with generalized epilepsy syndromes and 21 age- and sex-matched healthy controls. Serum orexin-A levels were measured using the enzyme-linked immunosorbent assay method. All patients underwent detailed neurological examination, electroencephalography, and neuroimaging as part of routine clinical evaluation.Results: No significant difference was observed in serum orexin-A levels between patients with generalized epilepsy syndromes and healthy control subjects (2745.3±2240.5 pg/mL and 2674.3±1794.5 pg/mL, respectively; p=0.697). The observed between-group effect size was negligible. In addition, serum orexin-A levels were not significantly associated with seizure frequency, seizure type, or electroencephalographic findings (all p>0.05).Conclusions: Serum orexin-A levels were not significantly altered in children with generalized epilepsy syndromes and were not associated with seizure-related clinical features. Despite supportive preclinical evidence, these findings suggest that peripheral orexin-A measurements may have limited utility as a biomarker in pediatric generalized epilepsy, highlighting the need for larger, multimodal studies to clarify the role of orexin signaling in epilepsy.